Europe Cardiac Marker Testing Market

Europe Cardiac Marker Testing Market Size (2022 to 2027):

The European cardiac marker testing market size is anticipated to grow at 8.94% CAGR from 2022 to 2027. The market is expected to be valued at USD 0.77 billion in 2022 and is expected to reach USD 1.19 billion by 2027.

The growing incidence of cardiovascular diseases and the increasing aging population in the European region are escalating the requirement for superior health solutions in the cardiac marker level, which is significantly boosting the market growth. Furthermore, growing funds from private and public organizations to promote research and clinical trials in biomarker testing is a positive sign of the growth rate of the market. Lifestyle changes in young people and amplifying stipulation for the point-of-care testing with cardiac biomarkers favor the market to grow further. Growing support from both government and non-government organizations is likely to bolster the growth rate of the market. 

Factors like unfavorable repayment schemes and administrative policies and an absence of skilled people hinder the cardiac marker testing market growth in Europe. Strict rules and guidelines made by the government towards the products and devices' approval process are hampering the market growth.

This research report on the Europe Cardiac Marker Testing Market has been segmented and sub-segmented into the following categories:

By Type:

• Troponin I & T
• CK-MB
• Myoglobin
• BNP
• HsCRP

By Product:

• Reagent
• Instrument
  • Chemiluminescence
  • Immunofluorescence
  • Immunochromatography
  • ELISA

By Disease:

• Acute Coronary Syndrome
• Myocardial Infarction
• Congestive Heart Failure

By Testing:

• Lab
• POC

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe.

Regional Analysis:

Europe held the second-largest share in the global market in 2019. Factors such as public-private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars are the key factors aiding the growth of the markets.

The German cardiac marker testing market is expected to hold the largest share in the European market during the forecast period. Growing occurrences of cardiovascular diseases and ongoing clinical trials for recognizing new cardiac markers are bolstering the growth of the cardiac marker testing market in the region. New product launches and approvals from the FDA are accelerating the growth. A growing number of patients with acute myocardial infarction among the emergency departments and the increasing rate of the lifespan of patients suffering from problems associated with heart by diagnosing the cardiac diseases are enhancing the growth rate of the market. Other nations existing in the region are likely to have considerable growth in the forthcoming years.

Prominent Companies leading the Europe Cardiac Marker Testing Market Profiled in the report are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, and Guangzhou Wondfo Biotech Co. Ltd.